TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Can understand and provide signed informed consent, request for medical records and/or subject privacy form if applicable according to local regulations~2. Has a clinical diagnosis of idiopathic Parkinson's disease with a minimum duration of 1 year, defined as the presence of at least three of the following cardinal features, in the absence of alternative explanations or atypical features:~   1. rest tremor~  2. rigidity~  3. bradykinesia and/or akinesia~  4. postural and gait abnormalities~3. Meets clinical criteria for depression with Parkinson's disease as listed in the NINDS/NIMH Guidelines~4. If currently taking an anti-depressant, is being treated with only one SSRI or SNRI antidepressant at a dose within the US FDA-approved dose range. Subjects who are currently taking a second antidepressant or antidepressant augmentation agent at a sub-therapeutic dose or for an inadequate duration at Screening, and can be discontinued from this agent before the Baseline visit (in the opinion of the Investigator), may be eligible for the study.~5. Is on a stable dose of anti-Parkinson's medication for 1 month prior to Screening~6. If the subject is female, she must be of non-childbearing potential or agree to use two methods of clinically acceptable contraception~Exclusion Criteria:~1. Use of an antipsychotic within 3 weeks or 5 half-lives of Baseline (whichever is longer)~2. Had a myocardial infarction within the 6 months prior to Screening~3. Has a known personal or family history or symptoms of long QT syndrome~4. Evidence of severe or medically significant hepatic or renal impairment on laboratory tests as assessed by the Investigator or Medical Monitor~5. Has a history of PD psychosis, schizophrenia, or other psychotic disorder, or bipolar I or II disorder.~6. Actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)~7. Is pregnant or breastfeeding~8. Has previously been treated with pimavanserin or is currently taking pimavanserin~9. Has a sensitivity to pimavanserin or its excipients~10. Is judged by the Investigator or the Medical Monitor to be inappropriate for the study~Additional inclusion/exclusion criteria apply. Subjects will be evaluated at screening to ensure that all criteria for study participation are met.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Drug - pimavanserin (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: VAccination to Improve Clinical outComes in Heart Failure Trial: a Feasibility Study (VACC-HeFT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adults \> 18 years old~2. Able to give informed consent~3. Systolic or diastolic dysfunction~4. Previously or currently symptomatic heart failure~5. Stable on current heart failure drug therapy regimen for \> 30 days and no change in heart failure drug therapy regimen on day of enrollment~6. Hospitalization (for any reason) in last 12 months~7. Received influenza vaccination the prior season~Exclusion Criteria:~1. History of allergic reaction or adverse event to influenza vaccine~2. Documented severe allergy to egg products~3. Unwilling or unable to give consent~4. Moderate to severe acute febrile illness at baseline~5. Immunologic conditions that may affect immune responses per clinical judgment of the investigators~6. Use of immunosuppressants or immunomodulating therapies within 3 months of the study, including prednisone, cyclosporine, tacrolimus, methotrexate, azathioprine, mycophenolate mofetil, cyclophosphamide, and injectable interferons~7. Participation in a clinical trial within 30 days~8. Absence for more than 7 consecutive days during the surveillance period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dose influenza vaccine (Type: ACTIVE_COMPARATOR): Standard dose (45ug) influenza vaccine will be administered intramuscularly
- High dose influenza vaccine (Type: ACTIVE_COMPARATOR): High dose (180ug) influenza vaccine will be administered intramuscularly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tamoxifen in Treatment of Acute Mania

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. diagnosis of BD I, most recent episode, manic or mixed,~2. ages 18-65,~3. Young Mania Rating Scale (YMRS) score \> 20 at screening and baseline,~4. providing written informed consent.~Exclusion Criteria:~1. currently pregnant, planning to become pregnant, or breast feeding,~2. history of any coagulopathies, deep vein thrombosis, pulmonary embolus,~3. a history of hypersensitivity to tamoxifen,~4. drug screen positive for any drug of abuse at screening, active substance abuse in the past 2 weeks or substance dependence in the past 2 months (except nicotine and caffeine),~5. diagnosis of schizophrenia, dementia, delirium, seizure disorder, obsessive compulsive disorder, or major cardiac, hepatic or renal disease that is unstable or that requires medical care,~6. administration of any other investigational drug in the last 30 days,~7. clinically significant suicidal or homicidal ideation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tamoxifen Citrate (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating the Safety and Efficacy of Autologous Non-Hematopoietic Peripheral Blood Stem Cells in COVID-19

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* RT-PCR Laboratory confirmation of COVID-19.~* Male or female aged ≥ 18 years.~* Interstitial lung change ≥ 3 judged by Lungs Lobar based scoring according to computed tomography (CT) scans.~* Hospitalized and symptomatic patients, referring one or more of the following symptoms (fever, cough, or shortness of breath), in association with (at least one): tiredness, runny nose, headache, sore throat, chills, muscle pain, or new loss of taste or smell).~* Ability to comply with test requirements and peripheral blood stem cells collection.~* The patient or legal representative agrees to participate in the study, and signs the SENTAD-COVID Study informed consent form.~Exclusion Criteria:~* Pediatric patients (aged \< 18 years).~* Diagnosis of any kind of shock.~* Organ transplants in the past 3 months.~* Patients receiving immunosuppressive therapy.~* Diagnostic of Hepatitis B Virus (HBV) infection.~* Diagnostic of Human Immunodeficiency Virus (HIV) infection or Acquired Immunodeficiency Syndrome (AIDS).~* Current diagnosis of cancer.~* History of malignancies in the past 5 years.~* Pregnant or lactating women.~* Have participated in other clinical trials in the past 3 months.~* Inability to comply with test requirements and peripheral blood stem cells collection.~* Inability to provide informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): Autologous Non-Hematopoietic Peripheral Blood Stem Cells (NHPBSC) therapy as add-on COVID-19 standard care.
- Group B (Type: ACTIVE_COMPARATOR): COVID-19 Standard care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Daylight PDT for Actinic Keratoses: a Multicentre Study Comparing Two Photosensitizers (BF-200 ALA Versus MAL)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with widespread AK lesions symmetrically on face or scalp (at least 3 actinic keratoses symmetrically on face or scalp)~* AKs of grade I-II~Exclusion Criteria:~* Thick grade III AKs~* Previous treatment for actinic keratosis on the same skin area during preceding 6 months~* Porfyria or solar dermatitis~* Allergy for photosensitizers used in the study~* Pregnant or breastfeeding patients~* Impaired general condition (patient can't manage required 2 hours in sunlight outdoors)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Actinic keratosis patients (Type: EXPERIMENTAL): Participant's AKs in facial skin or scalp are first clinically graded and demarcated in two symmetric treatment areas on different sides of face. The areas will be curettaged thinly and next a SPF20 sun protection cream is applied on all sun-exposed areas of the skin. Then a 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid) gel is applied on one treatment side and MAL (methyl 5-aminolevulinate) cream on the other side. The sides will be randomized and the participant doesn't know which side is treated with which light sensitizer. After appropriate absorption time of 30 minutes the patients will be taken to the hospital balcony or yard for 2 hour illumination with natural daylight to accomplish the phototoxic reaction. Maximum dosage of light sensitizer will be 2 grams.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Peritoneal Damage in Laparoscopic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients older than 18 years, signed informed consent, undergoing laparoscopic cholecystectomy for symptomatic cholelithiasis or gallbladder polyps.~Exclusion Criteria:~* Emergency surgery.~* Previous surgery at supramesocolic compartment.~* Previous peritoneal inflammatory process.~* Pregnancy or breastfeeding.~* Patient refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Low pneumoperitoneum pressure. (Type: EXPERIMENTAL): Pneumoperitoneum pressure at 8 mmHg or lower.
- standard pneumoperitoneum pressure (Type: ACTIVE_COMPARATOR): Pneumoperitoneum pressure at 12 mmHG or higher

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Duration for Abdominal Tuberculosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Newly diagnosed patients with Intestinal TB or Peritoneal TB~* Has not received ATT for Tuberculosis any where in the body during past 5 years~* Patients having good general health and not too sick.~* Patients willing and likely to comply with the study procedures and follow up~* Patients should give informed consent.~Exclusion Criteria:~* Eighteen year is a cut off age for definition of adult and pediatric and adolescent medicine. The dosing of drugs are different in these two age groups. Therefore we plan to include patients of more than 18 years of age with abdominal TB in this study.~* Intake of ATT during the past 5 years~* Doubtful diagnosis~* Crohn's disease~* Patients with HIV and AIDS may have another systemic opportunistic infections including GI infections like cryptosporidiosis, Microsporidiosis or isosporiasis. There may be an overlap of GI manifestations such as diarrhea, abdominal pain, anemia, fever. Therefore, assessment of response to anti-tuberculosis therapy may be blurred. In order to keep the study group homogenous for comparison, we plan to exclude all those with HIV infection~* Chronic Liver Disease~* Associated significant co-morbidities~* H/O Sensitivity~* Peritoneal carcinomatosis~* Patients must not been used investigational agents during the past 6 months~* Unwilling patient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1: Category I treatment for 6 months (Type: ACTIVE_COMPARATOR): Anti-tuberculosis drugs
- Arm 2: Category I treatment for 9 months (Type: ACTIVE_COMPARATOR): Anti-tuberculosis drugs,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Effect of Esomeprazole on SYN-004 Degradation of Ceftriaxone In Adults With an Ileostomy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* The subject has a functioning ileostomy that has been in place for ≥ 3 months.~* The subject is male or female between the ages of 18 and 80 years, inclusive.~* Other than a functioning ileostomy, the subject is free from clinically significant illnesses or disease.~Exclusion Criteria:~* Subjects who have active hepatic, small intestine, or biliary tract disease.~* Subjects who have active ulcerative colitis, Crohn's disease, other inflammatory bowel disease.~* Subjects with known malignancy requiring treatment \< 6 months prior to study screening.~* Subjects who have, in the opinion of the investigator, significant concurrent medical illness.~* Subjects who are currently taking concomitant medications which may interfere with study evaluation.~* Subjects who have received an investigational drug within 30 days or within a time period consistent with a washout period of 5 half-lives, whichever is longer, of the first dose of ceftriaxone.~* Subjects with a known history of allergy to any cephalosporin, penicillin or any β-lactam antibiotic.~* Subjects who have known active malabsorption syndromes(s) that, in the judgment of the investigator, could compromise the objectives of the study.~* Subjects who have used any oral, intramuscular, or IV anti-microbial medication during the last 3 week

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- 150 mg SYN-004 (Type: EXPERIMENTAL): There will be 2 in-house treatment periods: in Treatment Period 1, subjects will receive 2 oral doses of 150 mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone, and in Treatment Period 2, subjects will receive 2 oral doses of 150mg SYN-004 (two 75 mg capsules) and 1g ceftriaxone in the presence of steady-state esomeprazole; Treatment Periods 1 and 2 will be separated by a 5- to 7-day run-in phase, during which subjects will self-administer 40 mg of esomeprazole once daily (QD) in the morning, at home.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MT2014-25: Haplo NK With SQ IL-15 in Adult Relapsed or Refractory AML Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria (Recipient):~* Meets ONE of the following disease criteria:~  1. Primary AML induction failure: no CR after 2 or more induction attempts~ 2. Relapsed AML or Secondary AML (from MDS or treatment related): not in CR after 1 or more cycles of standard re-induction therapy~ 3. AML relapsed \> 2 months after transplant: No re-induction required, and no more than 1 re-induction cycle is allowed.~ 4. Relapsed AML for patients \> 60 years of age the 1 cycle of standard chemotherapy is not required if either of the following criteria is met:~     * Relapse within 6 months of last chemotherapy~    * BM blast count \< 30% within 10 days of starting protocol therapy~* Available related HLA-haploidentical donor (aged 14 to 75 years) by at least Class I serologic typing at the A\&B locus~* Karnofsky Performance Status ≥ 60%~* Patients must have adequate organ within 14 days (28 days for pulmonary and cardiac) of study registration~* Able to be off prednisone or other immunosuppressive medications for at least 3 days prior to NK cell infusion (excluding preparative regimen pre-medications).~* Agrees to use contraception prior to study entry and for the duration of study participation.~Exclusion Criteria (Recipient):~* Bi-phenotypic acute leukemia.~* Transplant \< 60 days prior to study enrollment.~* Active autoimmune disease.~* History of severe asthma~* Uncontrolled intercurrent illness~* New or progressive pulmonary infiltrates on screening chest x-ray or chest CT scan that has not been evaluated with bronchoscopy~* Pleural effusion large enough to be detectable on chest x-ray.~* Pregnant women~* History of HIV, active or chronic hepatitis B, hepatitis C or HTLV-I infection~* Known hypersensitivity to any of the study agents used~* Received investigational drugs within the 14 days of study registration.~* Known active CNS involvement.~Criteria For Initial Donor Selection:~* Related donors (sibling, parent, offspring, parent or offspring of an HLA identical sibling).~* 14-75 years of age.~* At least 40 kilogram body weight.~* In general good health as determined by the evaluating medical provider.~* HLA-haploidentical donor/recipient match by at least Class I serologic typing at the A\&B locus.~* Not pregnant.~* Able and willing to undergo apheresis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Preparative Regimen and SubQ rHuIL-15 (Type: EXPERIMENTAL): Preparative Regimen of Fludarabine and Cyclophosphamide~IL-15 Activation of Donor NK Cells:~IL-15 to Facilitate NK Cell Survival and Expansion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Investigating the Renal Tolerability, Efficacy, and Safety of a CNI-free Versus a Standard Regimen in de Novo Heart Transplant (HTx) Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Heart transplantation, 3 months prior to enrollment~* Patients have to receive an immunosuppressive regimen with Sandimmun® Optoral, Certican® and corticosteroids~* Sufficient graft function~* Sufficient renal function~* Females capable of becoming pregnant must have a negative serum pregnancy test within 7 days prior to or at baseline, and are required to practice an approved method of birth control for the duration of the study and for a period of 6 weeks following discontinuation of study medication, even where there has been a history of infertility~Exclusion criteria:~* Multi-organ recipients, re-transplantation, or previous transplant with any other organ.~* Patients who are recipients of A-B-O incompatible transplants~* Cold ischemia time \>6 hours~* Historical or current peak PRA of \> 25% at time of transplantation~* Already existing antibodies against the HLA-type of the receiving transplant Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- CNI-regimen (Type: ACTIVE_COMPARATOR): CNI-regimen: cyclosporine A (CyA) or tacrolimus (TAC) with everolimus (EVR) with corticosteroids
- CNI-free-regimen (Type: EXPERIMENTAL): CNI-free regimen: everolimus (EVR) with MPA (either MMF or enteric coated mycophenolate sodium (EC-MPS)) and corticosteroids

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Orthotic Use for Chronic Low Back Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Males and females must be at least 18 years old.~2. Subjects must be symptomatic with current pain between T12 and the Sacroiliac joints with or without radiating pain.~3. Symptoms must have been present for at least three months.~Exclusion Criteria:~1. Use of custom-made shoe orthotics in the past year~2. Brain disorders (i.e.: dementia or Alzheimer's Disease) that would lead to difficulty in questionnaire completion.~3. Active conservative care (such as physical therapy or chiropractic care) for the low back received in the last six months (excluding the use of oral medications or daily at-home exercises for general well-being). We do not want to over-treat the patient or have any cross-over effects within this study from previous treatment.~4. Not fluent or literate in the English language. We will not be able to provide multiple translators within this pilot study.~5. Current or future litigation for low back pain.~6. Chronic pain other then low back pain such as fibromyalgia~7. Low back surgery in last six months.~8. Other conditions that may affect the outcomes of this study or exclude patients from participation in the study, including contraindications to orthotic use.~9. Peripheral neuropathy due to disorders such as diabetes.~10. Low back or leg pain that is not reproducible.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Orthotic group (Type: ACTIVE_COMPARATOR): Subjects are asked to wear custom-made shoe orthotics for a 12 week study period.
- Shoe Orthotic Wait group (Type: OTHER): The group serves as a cross-over control group. Subjects are asked to avoid any new therapies for the first 6 weeks of the 12 week study and during the last 6 weeks they are fitted for the custom-made shoe orthotics.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete